Complaints Outcomes

Search

Search Results

Search Again
Khun-Khun, Amandeep Singh (Jun 12, 2019)
  1. Nature of Action: The Inquiry Committee of the College of Pharmacists of British Columbia (the “College”) conducted an investigation into the practice of now former registrant Amandeep Singh Khun-Khun (the “Former Registrant”), pursuant to section 33(4) of the Health Professions Act, R.S.B.C. 1996, c. 183. The Inquiry Committee and the Former Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the Health Professions Act.

  2. Effective date: June 12, 2019

  3. Name of registrant: Amandeep Singh Khun-Khun

  4. Location of Practice: Vancouver, BC

  5. Admissions and Acknowledgements:

    Between January 1, 2014 and November 5, 2017, over 15,000 transactions for over-the-counter (“OTC”) and/or vitamin products were processed on a daily or weekly basis on the PharmaNet records of seven individuals. These seven individuals were not prescribed and had not received any of the OTC and/or vitamin products processed on their PharmaNet records. Most of the seven individuals stated that they had not willingly consented to having these transactions on their PharmaNet records.

    These transactions all originated from a pharmacy where the Former Registrant was the pharmacy manager and owner.

    The Former Registrant admitted that he had directed pharmacy assistants to process transactions weekly on PharmaNet in order to artificially inflate the pharmacy’s prescription count. The pharmacy assistants used the registration numbers of various pharmacist registrants as the dispensing pharmacist and/or prescriber for each transaction. The majority of pharmacy registrants stated that their registration numbers were used without their willing consent or knowledge. Many of these transactions were also backdated.

    The Former Registrant’s actions and direction enabled the inappropriate access and use of PharmaNet records, enabled the inappropriate access and use of pharmacist registration numbers, and caused PharnaNet records to be inaccurate and not current.

  6. Disposition:

    The Former Registrant entered into a Consent Agreement with the College’s Inquiry Committee, wherein the Former Registrant consented to the following terms: 

    1. To suspend his registration as a pharmacist for a total of 540 days, to commence upon his reinstatement to Full Pharmacist status;

    2. To not be a pharmacy manager, director, owner (direct or indirect), shareholder, and preceptor for pharmacy students for a period of five years from the date that his suspension ends;
       
    3. To successfully pass the College’s Jurisprudence Exam;

    4. To successfully complete and pass an ethics course for healthcare professionals; and.

    5. To pay a $30,000.00 fine.

  7. Rationale:

    The Inquiry Committee considered that the Former Registrant’s intentional directing of weekly transactions which enabled the processing of over 15,000 false prescriptions on PharmaNet involved significant breaches of confidentiality and trust. The fact that his actions led to an inflated prescription count, from which the Inquiry Committee believed he gained financial and personal benefit, made his conduct even more serious.

    His actions were considered serious contraventions of legislation involving use and protection of personal information, appropriate use and access of PharmaNet and patient records, supervision of pharmacy assistants, and his role as a pharmacy manager. He also contravened standards of the Code of Ethics involving protecting and promoting the well-being of patients, benefitting society, committing to personal and professional integrity, and participating in ethical business practices. The Inquiry Committee also considered that the Former Registrant had previously consented to remedial undertakings to fully comply with ethical requirements, and he had breached these undertakings for this current matter. The totality of the Former Registrant’s serious, intentional, and repeated conduct amounted to significant professional misconduct, and the Inquiry Committee considered that the Former Registrant required the above-referred-to remediation and deterrence in order to come into compliance.

    The Inquiry Committee considered the terms of the Consent Agreement necessary to protect the public, as well as send a clear message of deterrence to the profession. Inappropriate access and use of personal information, especially without consent, compromises the public’s trust in the pharmacy profession as a whole. At all times, registrants must uphold legislative requirements and ethical obligations to appropriately access, use, and protect personal information.

Ladha, Azizabegum (Jun 7, 2019)
  1. Nature of Action: The Inquiry Committee of the College of Pharmacists of British Columbia (“the College”) conducted an investigation into the practice of Azizabegum Ladha (the “Registrant”), pursuant to section 33(4) of the Health Professions Act, R.S.B.C. 1996, c. 183 (“HPA”).

    The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the HPA.

  2. Effective date: June 7, 2019

  3. Name of registrant: Azizabegum Ladha 

  4. Location of Practice: Surrey, BC

  5. Admissions and Acknowledgements:

    Between January 2016 and July 2016, the Registrant worked at two different pharmacies, one of which she was the pharmacy manager. During this time, the following pharmacy practice issues and contraventions of legislation occurred, of which she had direct involvement:

    1. She did not provide adequate pharmacist/patient consultations for refill medications;

    2. She dispensed Schedule I medication in a manner that was not authorized in the prescriptions;

    3. She processed inaccurate and non-current transactions on PharmaNet;

    4. She did not review PharmaNet prior to dispensing prescriptions; and

    5. She did not take reasonable steps to confirm the identity of a patient before dispensing medication for this patient.

  6. Disposition:

    The Registrant entered into a Consent Agreement with the College’s Inquiry Committee, wherein the Registrant consented to the following terms:

    1. To suspend her registration as a pharmacist for a total of 30 consecutive days;

    2. To not be a pharmacy manager and preceptor for a period of 18 months from the date that her suspension ends;
       
    3. To pay a fine in the amount of $5,000.00; and

    4. To successfully complete and pass the “BC Pharmacy Manager Training Program” offered by the British Columbia Pharmacy Association.

  7. Rationale:

    The Inquiry Committee was concerned that the Registrant had previously consented to undertakings and a reprimand related to her pharmacy practice, from which she should have remediated. However, in this current matter she contravened practice standards which could have endangered patient health. The Inquiry Committee therefore considered the totality of the Registrant’s conduct to be serious, and that she required further remediation and deterrence in order to come into compliance.

    The Inquiry Committee considered the terms of the Consent Agreement necessary to protect the public, as well as send a clear message of deterrence to the profession.

Sam, William Byron (Jun 6, 2019)

Pursuant to section 35(1)(b) of the Health Professions Act, the Inquiry Committee has ordered a suspension of the registration of registrant William Byron Sam pending completion of an investigation, effective June 6, 2019. The Registrant will not be able to practice pharmacy in the province of British Columbia while his registration is suspended. The Inquiry Committee considered the suspension necessary to protect the public.

The Inquiry Committee was satisfied on the information before it that there is a real risk to the public should this interim order not be put in place. The Registrant was knowingly operating an unlicensed pharmacy, contrary to the directions of the College. Serious public risk indicators were present within the pharmacy. The Registrant continued to display an inexplicable pattern of responsiveness to and disregard for the College and its regulatory requirements and its communications with him.

Note: Suspensions ordered by the Inquiry Committee under section 35(1)(b) of the Health Professions Act are made to protect the public during an investigation or pending a hearing of the Discipline Committee. Orders made under this section relate to matters which are and remain unproven unless admitted by a registrant or determined by the Discipline Committee.

Tam, Sing Man (May 27, 2019)
  1. Nature of Action: The Inquiry Committee of the College of Pharmacists of British Columbia (the “College”) conducted an investigation into the practice of Sing Man Tam (the “Registrant”), pursuant to section 33(4) of the Health Professions Act, R.S.B.C. 1996, c. 183. The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the Health Professions Act.

  2. Effective date: May 27, 2019

  3. Name of registrant: Sing Man Tam​

  4. Admissions and Acknowledgements:

    On October 13, 2015, the College received correspondence from the BC Ministry of Health regarding potential pharmacy practice concerns at the Pharmacy, arising from a PharmaCare Audit of the Pharmacy that covered the time period between September 1, 2012 and August 31, 2014 (the “Audit Period”).  Further to the College’s investigation of those practice concerns, the Registrant acknowledged

    1. prescriptions were missing date or quantity to dispense,

    2. prescriptions were filled under the incorrect prescriber,
       
    3. a prescription was dispensed for the wrong dose,

    4. prescriptions were written by the prescriber as daily witness ingestion but were processed under the Drug Identification Number (“DIN”) for methadone given without direct interaction
       
    5. a prescription was written by the physician for daily witness ingestion but was processed under the DIN for delivery of methadone, without authorization,

    6. medication reviews were submitted to PharmaNet that did not have any supporting documentation,

    7. prescriptions for Hepatitis C medications were not submitted to PharmaNet on the day of claimed dispense,
       
    8. prescriptions were written by the physician as daily dispense, but were filled and submitted to PharmaNet as a 7 days’ supply, with no documentation of a prescriber’s authorization to do so,

    9. a prescription was filled as a verbal authorization with incomplete documentation,

    10. a methadone prescription was billed on a day marked as “missed” on the ingestion logs,

    11. a prescription adaptation was conducted without adequate documentation,

    12. a methadone prescription did not have a part fill accountability log, and

    13. a methadone prescription was provided as delivery without prescriber authorization.

  5. Disposition:

    The Registrant entered into a Consent Agreement with the College’s Inquiry Committee, wherein the Registrant consented to the following terms:

    1. having a Letter of Reprimand placed permanently on his registration record;

    2. payment of a fine in the amount of $10,000;
       
    3. an undertaking to:

      1. not repeat the conduct to which this matter relates,
         
      2. thoroughly review and read legislation, standards and policies relevant to the conduct to which this matter relates, and thereafter submit a Declaration of Understanding regarding the legislation, standards and policies reviewed and read,
         
      3. complete the BC Pharmacy Manager Training Course as well as coursework relating to opioid agonist therapy,
         
      4. successfully complete the College’s Jurisprudence Exam,
         
      5. at all times prior to completing the BC Pharmacy Manager Training Course and successfully completing the College’s Jurisprudence Exam only provide the services of a pharmacist when a least one other full pharmacist registrant is present with him in the pharmacy, and
         
      6. at all times after delivering the Declaration of Understanding, completing the BC Pharmacy Manager Training Course and coursework relating to methadone maintenance treatment, and successfully completing the College’s Jurisprudence Exam, be knowledgeable of and abide by all legislation and policy governing the practice of pharmacy.

       

  6. Rationale:

    The Inquiry Committee considered that in this case, the cumulative weight of the practice deficiencies demonstrated inadequate diligence and oversight in the Registrant’s practice, noting that many of the substantiated practice deficiencies were substantive, and not simply administrative. Accurate record keeping and documentation are fundamental to providing safe pharmaceutical care. Therefore, the Committee considered the Registrant’s conduct to be serious, and that the Registrant required both remediation and deterrence in order to come into compliance. The Inquiry Committee considered the terms of the Consent Agreement necessary to protect the public, as well as send a clear message of deterrence to the profession.

Mbamy, Joelle (May 23, 2019)

Pursuant to section 35(1)(a) of the Health Professions Act, R.S.B.C. 1996, c. 183 (“HPA”), effective May 23, 2019, the Inquiry Committee of the College of Pharmacists of British Columbia has made an order to impose limits and conditions on the pharmacy practice of the registrant Joelle Mbamy (the “Registrant”) pending a hearing of the Discipline Committee.

The Registrant will be restricted from dispensing any narcotic or controlled drug substance intended for Opioid Agonist Treatment. This limit and condition will become effective on June 7, 2019 to allow sufficient time to transition patients to another pharmacy.

The Registrant will be restricted from compounding any medication and preparing or dispensing any medication intended for intravenous administration.

The Inquiry Committee considered this action necessary to protect the public.

While practicing as a pharmacist, the Registrant is alleged to have shown a continuing pattern of providing Opioid Agonist Treatment without abiding by the legislative requirements. While practicing as a pharmacist, the Registrant is alleged to have prepared and dispensed intravenous drug product under unsanitary conditions.

Note: Limits and conditions ordered by the Inquiry Committee under section 35(1)(a) of the HPA are made to protect the public during an investigation or pending a hearing of the Discipline Committee. Orders made under this section relate to matters which are and remain unproven unless admitted by a registrant or determined by the Discipline Committee.

Citation

Damji, Salma Sadrudin (May 15, 2019)
  1. Nature of Action: The Inquiry Committee of the College of Pharmacist of British Columbia (the “College”) conducted an investigation into the practice of Salma Sadrudin Damji (the “Registrant”), pursuant to section 33(4) of the Health Professions Act (“HPA”), R.S.B.C. 1996, c. 183. The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the HPA.

  2. Effective date: May 23, 2019

  3. Name of registrant: Salma Sadrudin Damji

  4. Location of Practice: Vancouver, BC

  5. Admissions and Acknowledgements:

    Between January 2013 and January 2018, using a prescription pad from a medical clinic, the Registrant falsified prescriptions using three patient names and two physician names. The falsified prescriptions resulted in over sixty-two transactions processed on PharmaNet. The medications for these transactions were all Schedule I drugs, which required authorized prescriptions.

    The Registrant used the names and forged the signatures of two physicians as prescribers on these falsified prescriptions, all without the knowledge, consent or authorization of these physicians. The Registrant inappropriately used personal health information and created inaccurate PharmaNet records for the involved patients. By doing so, the Registrant placed the three patients whose name she used at risk of harm, in case their PharmaNet records ever needed to be accessed for legitimate reasons.

  6. Disposition:

    The Registrant entered into a Consent Agreement with the College’s Inquiry Committee, wherein the Registrant consented to terms that include (but not limited to) the following:

    1. To suspend her registration as a pharmacist for a total of 90 days;

    2. To not be pharmacy manager, director, and/or owner of a pharmacy, shareholder in a corporation that owns a pharmacy, and a preceptor for pharmacy students for a period of three years;
       
    3. To write apology letters to persons affected by her conduct;

    4. To complete and successfully pass an ethics course for healthcare professionals; and

    5. To pay a fine of $1,000.

  7. Rationale:

    The Inquiry Committee considered that in this case, in addition to the serious misconduct, the Registrant placed herself and others at significant risk of harm, inappropriately used personal information, and created inaccurate PharmaNet records. Her actions were a serious contravention of standards in the Code of Ethics, and compromised the public’s trust in the pharmacy profession as a whole.

    The Inquiry Committee therefore determined that the Registrant required serious remediation and deterrence regarding her conduct. After also considering significant mitigating factors, the Inquiry Committee considered the terms of the Consent Agreement appropriate to protect the public, as well as send a clear message of deterrence to the profession.

Pharmacist Registrant 27 (May 12, 2019)

The Inquiry Committee, pursuant to s. 32.2(4)(b)(ii) of the Health Professions Act, has reached an Agreement with the pharmacist registrant to voluntarily suspend the registration as a pharmacist effective May 12, 2019. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.

Nekoi Panah, Davood (May 2, 2019)
  1. Nature of Action: The Inquiry Committee of the College of Pharmacists of British Columbia (“the College”) conducted an investigation into the practice of Davood Nekoi Panah (the “Registrant”), pursuant to section 33(4) of the Health Professions Act, R.S.B.C. 1996, c. 183 (“HPA”).

    The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the Health Professions Act.

  2. Effective date: May 2, 2019

  3. Name of registrant: Davood Nekoi Panah

  4. Location of Practice: North Vancouver, BC

  5. Admissions and Acknowledgements:

    Between December 16, 2016 and March 3, 2017, while the Registrant was pharmacy owner, pharmacy manager, and pharmacist at a pharmacy, the following pharmacy practice issues and contraventions of legislation occurred:

    1. He provided monetary incentives to a patient;

    2. He did not provide adequate pharmacist/patient consultation for refill medications;
       
    3. He dispensed Schedule I medication without having an authorized prescription;

    4. He dispensed Schedule I medication in a manner that was not authorized in the prescription;
       
    5. He dispensed Schedule I medications in unlabelled or inappropriately labelled prescription containers;

    6. He was directly involved in processing inaccurate and non-current transactions on PharmaNet; and

    7. He did not take reasonable steps to confirm the identity of patients before dispensing medication to these patients.
       
  6. Disposition:

    The Registrant entered into a Consent Agreement with the College’s Inquiry Committee, wherein the Registrant consented to the following terms:

    1. To suspend his registration as a pharmacist for 60 consecutive days commencing September 4, 2019;

    2. To not be a pharmacy manager and preceptor for a period of two years from the date that his suspension ends;
       
    3. To pay a fine in the amount of $10,000.00;

    4. To successfully complete and pass an ethics course for healthcare professionals;
       
    5. To successfully complete and pass the “BC Pharmacy Manager Training Program” offered by the British Columbia Pharmacy Association;

    6. To appear before the Inquiry Committee for a verbal reprimand; and

    7. To thoroughly review and read legislation and standards of practice relevant to the conduct to which this matter relates, and thereafter submit a Declaration of Understanding regarding the legislation and standards of practice reviewed and read.
       
  7. Rationale:

    The Inquiry Committee considered that the Registrant consistently contravened practice standards, knowingly neglected his basic duties as a pharmacist, and knowingly committed or allowed actions that were unethical and could potentially endanger patient health. The totality of his conduct was serious and demonstrated a breach of trust.

    Although this was the first instance the Registrant’s practice has been reviewed by the Inquiry Committee, based on his conduct in this case the Inquiry Committee considered it appropriate that the terms of the Consent Agreement not only be remedial, but also one that serves as a significant deterrent and sends a clear message to both the profession and the public that the College does not tolerate this type of conduct.

Akhnouh, Patrick Kamal (Apr 11, 2019)
  1. Nature of Action: The Inquiry Committee of the College of Pharmacists of British Columbia (the “College”) conducted an investigation into the practice of Patrick Kamal Akhnouh (the “Registrant”), pursuant to section 33(4) of the Health Professions Act, R.S.B.C. 1996, c. 183. The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the Health Professions Act.

  2. Effective date: April 11, 2019

  3. Name of registrant: Patrick Kamal Akhnouh

  4. Location of Practice: Langley, BC

  5. Admissions and Acknowledgements:

    On October 4th, 2018, the Registrant dispensed and administered the incorrect vaccination to a patient. The Registrant learned of the error the same day and altered the patient’s PharmaNet record to reflect the correct vaccination, thereby making the patient’s PharmaNet record inaccurate. The Registrant did not inform the patient or the documented prescriber of the error at this time. The error was later self discovered by the patient and reported to the Registrant.

    After initiation of the College’s investigation into this matter, the Registrant again altered the patient’s PharmaNet record to reflect what had actually been dispensed to the patient.

  6. Disposition:

    The Registrant entered into a Consent Agreement with the College’s Inquiry Committee, wherein the Registrant consented to terms that include (but are not limited to) the following:

    1. To make significant procedural changes to his pharmacy practice;

    2. To re-take and successfully complete the Practical Administration of Injections for B.C. Pharmacists Workshop;
       
    3. To not perform or administer injections until the Practical Administration of Injections for B.C. Pharmacists Workshop has been successfully completed;To not perform or administer injections until the Practical Administration of Injections for B.C. Pharmacists Workshop has been successfully completed;

    4. To complete and successfully pass an ethics course for healthcare professionals; and
       
    5. To pay a fine of $500.

  7. Rationale:

    The Inquiry Committee considered that in this case, the Registrant placed his patient at significant risk of harm when he altered the patient’s PharmaNet record and did not inform the patient or his prescriber of the error. His actions were a serious contravention of standards in the Code of Ethics, and likely would compromise the public’s trust in the pharmacy profession as a whole.

    The Inquiry Committee therefore determined the Registrant’s conduct to be serious, and that the Registrant required both remediation and deterrence in order to come into compliance. The Inquiry Committee considered the terms of the Consent Agreement appropriate to protect the public, as well as to send a clear message of deterrence to the profession.

Pharmacist Registrant 21 (Mar 29, 2019)

The Inquiry Committee has removed all limits and conditions from the pharmacist registrant’s registration, pursuant to a report and recommendation from the Registrant’s physician.


June 10, 2018
(March 29, 2019 - Limits and Conditions Removed)

The Inquiry Committee, pursuant to section 36(1) of the Health Professions Act, has reached a new Agreement with the pharmacist registrant to amend certain terms in the Agreement of May 1, 2017. The pharmacist registrant is now no longer subject to medical monitoring. All other limits and conditions will remain as part of the new Agreement for a minimum of six months, after which the Registrant’s medical condition may be reassessed. The Registrant has also agreed to begin a gradual return to work. The name of the Registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant respecting the condition.


May 1, 2017
(June 10, 2018 - Limits and Conditions Updated)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on July 27, 2016. Pursuant to section 36 of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings involving regular monitoring for fitness to practice pharmacy. The undertakings include, but are not limited to:

  1. Strictly adhering to the Registrant's routine medical monitoring program with the institution currently involved in his care and remaining on the monitoring program for a period of 12 months;

  2. Informing all managers and employers with whom Registrant gains employment of Registrant’s medical condition and the limits and conditions on Registrant’s registration pursuant to the Agreement;

  3. Ensuring that all managers and employers with whom Registrant gains employment submits a written statement to the College declaring their awareness of Registrant’s medical condition and the Agreement, and how they will accommodate and supervise Registrant working in pharmacy;

  4. Registrant will not work alone in a pharmacy setting, meaning that Registrant must never be the sole pharmacist in attendance at any time and that there must be another pharmacist or pharmacy assistant or pharmacy staff working with Registrant at all times;

  5. Registrant will not have access to narcotic-safe or physically process and/or otherwise prepare any prescriptions that require access to the narcotic safe;

  6. Registrant will not be involved in any way with ordering supplies of narcotic medications;

  7. The Registrant will not process and/or otherwise prepare any prescriptions that require access to the narcotic safe. In dispensing such prescriptions, the Registrant will only be involved in the intake, final check and pharmacist/patient counseling in accordance with the HPA Bylaws;

  8. The Registrant will be restricted from acting in the following roles in Registrant’s practice:

    1. an owner or manager of a pharmacy;
    2. a director of a corporation that owns a pharmacy; and
    3. a preceptor;

     

  9. The Registrant will notify the College, in writing or via e-mail, of:

    1. all changes in places of employment as a pharmacist
    2. all changes in residential address and phone number; and
    3. all changes in medical provider.

The Agreement will remain in place for a minimum of 12 months from the date of execution of the Agreement, following which the Registrant may submit information or documentation, including independent medical assessments, to support removing any or all of the above limits and conditions. The name of the Registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public.


July 27, 2016
(May 1, 2017 – Registration Reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an Agreement with the pharmacist registrant to suspend his registration as a pharmacist, effective July 27, 2016. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant's name has been withheld, pursuant to s. 39.3(4) of the Health Professions Act.


February 27, 2015
(July 27, 2016 – Registration Suspended)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on July 23, 2014. Pursuant to section 36 of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings involving regular monitoring for fitness to practice pharmacy. The undertakings include, but are not limited to:

  1. Strictly adhering to his routine medical monitoring program with the institution currently involved in the Registrant's care and remaining on the monitoring program for a period of 3 years;

  2. Informing all managers and employers with whom Registrant gains employment of Registrant’s medical condition and the limits and conditions on Registrant’s registration pursuant to the agreement;

  3. Ensuring that all managers and employers with whom Registrant gains employment submits a written statement to the College declaring their awareness of Registrant’s medical condition and the agreement, and how they will accommodate and supervise Registrant working in pharmacy;

  4. Registrant will not work alone in a pharmacy setting, meaning that Registrant must never be the sole pharmacist in attendance at any time and that there must be another pharmacist or pharmacy assistant or pharmacy staff working with Registrant at all times;

  5. Registrant will not have access to narcotic-safe or physically process and/or otherwise prepare any prescriptions that require access to the narcotic safe;

  6. Registrant will not be involved in any way with ordering supplies of narcotic medications;

  7. The Registrant will not process and/or otherwise prepare any prescriptions that require access to the narcotic safe. In dispensing such prescriptions, the Registrant will only be involved in the intake, final check and pharmacist/patient counseling in accordance with the HPA Bylaws;

  8. The Registrant will be restricted from acting in the following roles in Registrant’s practice:

    1. an owner or manager of a pharmacy;
    2. a director of a corporation that owns a pharmacy; and
    3. a preceptor;

  9. The Registrant will notify the College, in writing or via e-mail, of:

    1. all changes in places of employment as a pharmacist
    2. all changes in residential address and phone number; and
    3. all changes in medical provider.

The Agreement will remain in place for a minimum of three years from the date of execution of the Agreement, following which the Registrant will be assessed by a physician to determine whether or not continuation of monitoring is necessary. The name of the Registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public.


JULY 23, 2014
(FEBRUARY 27, 2015 – REGISTRATION REINSTATED)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an Agreement with the pharmacist registrant to suspend the registration as a pharmacist, effective July 23, 2014. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant's name has been withheld, pursuant to s. 39.3(4) of the Health Professions Act.

Pages